



FOR IMMEDIATE RELEASE:

**Micron Announces Positive Long-Term Patient Outcomes For  
World's First Wireless Microsize Permanent Injectable  
OAB Tibial Stimulator  
Regulatory Studies for Office Procedure Treatment of Incontinence  
To Take Place This Year**

MIAMI, Fla. (May 28, 2015) – Micron Medical Corporation, a medical device manufacturer and independent research institute headquartered in Miami Beach, Florida, today announced positive results for long-term patients using the world's first wireless micro-technology injectable tibial stimulator for the relief of overactive bladder (OAB). The device was placed last year in Zurich, Switzerland by leading urology pioneer Karl-Dietrich Sievert, M.D., chairman of Urology at the University of Salzburg. Patient outcomes show ongoing reduction of voiding episodes and more than 80 percent relief with a therapy that is administered only at night.

These preliminary results represent a life-changing technological breakthrough for the more than 200 million people worldwide that are afflicted with incontinence. To date, patients have had to make office visits routinely or undergo a surgery in the OR to utilize neuromodulation for relief of their OAB symptoms. The Micron technology, developed by scientists and engineers led by co-inventor and Micron Chairman Laura Tyler Perryman, uses a tiny injectable microchip device placed through a small needle that delivers small pulses of energy to electrodes near surrounding nerves, triggering a reaction that enables the brain to remap specific urge signals.

“The therapy is utilized for just eight hours a day, so it can be conveniently administered using only a sock worn during the evening or overnight,” said industry veteran and Micron Director James McGivern. “Chronic tibial stimulation affects multiple afferent paths to the micturition centers, possibly better serving patients than classic sacral neurostimulation over the long term.”

Dr. Sievert conducted the procedures live at the 2014 Swiss Continence Foundation Conference in Zurich last August. “I am pleased to report that our two patients who presented with OAB and a variety of other medical complications had long term positive outcomes and a reduction in incontinence episodes of greater than 80 percent on average, positively affecting their quality of life,” said Sievert. “The procedure was simple to perform, and I look forward to treating many patients with this novel therapy, which can be administered in a less costly way than other neuromodulation options.”

“I am extremely excited about this new technology developed by Micron. Now people with overactive bladder will have additional options, including the ability to receive a permanent implant with a far less invasive and complicated surgery in an office setting,” said Chris Winters, M.D., chairman of the Department of Urology, Louisiana State University. “The Micron Tibial System is well positioned to revolutionize the urology industry with an interventional method that most urologists will be able to easily integrate into their practices.”

While neuromodulation has been used for the treatment of OAB since 1997 with expensive systems and numerous large implanted parts and batteries, Micron’s novel tibial placement procedure requires just one implanted component: a microsize neurostimulator that can be implanted non-surgically by using only a needle and without the need for imaging equipment. This treatment offers a minimally invasive, outpatient office procedure resulting in a lower cost option for the industry and a patient option that is widely accepted since it is like acupuncture, but permanent.

Micron conducted short-term pilot studies in 2013 with encouraging results for the chronic tibial neurostimulation concept. The company plans to complete regulatory studies for CE Mark in 2015 and to seek FDA approval in 2016.

For more information about the Micron clinical trials, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## About Micron Medical Corporation

Micron Medical Corporation is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. Micron's goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management. <https://micronmed.com/index.php>.

###

Media Contacts: Jenna Hudson, Sonia Meyer, and Evan Nicholson at Glodow Nead Communications, 415.394.6500, [stimwaveapr@glodownead.com](mailto:stimwaveapr@glodownead.com).

